Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 7/20 | 0.44 |
| ▸ | RUVBL1 | Q9Y265 | 4/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29069814 | 1.00 | CIT (0.44) | CITRUVBL1ITGB1ITGA4AAK1 | |
| SCHEMBL29069818 | 1.00 | CIT (0.44) | CITRUVBL1ITGB1ITGA4AAK1 | |
| SCHEMBL29069797 | 0.87 | CIT (0.44) | CITRUVBL1AAK1ROCK2TAAR1 | |
| SCHEMBL29069795 | 0.87 | CIT (0.44) | CITRUVBL1AAK1ROCK2TAAR1 | |
| SCHEMBL29069817 | 0.84 | CIT (0.60) | CITHDAC8ROCK2TAAR1 | |
| SCHEMBL29069813 | 0.84 | CIT (0.60) | CITHDAC8ROCK2TAAR1 | |
| SCHEMBL4525580 | 0.82 | AAK1 (0.58) | CITAAK1HDAC8ROCK2TAAR1 | |
| SCHEMBL10267381 | 0.82 | AAK1 (0.58) | CITAAK1HDAC8ROCK2TAAR1 | |
| SCHEMBL26909942 | 0.79 | ITGA4 (0.44) | ITGB1ITGA4 | |
| SCHEMBL26909948 | 0.79 | ITGA4 (0.44) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600728-B2 | Interleukin-17 inhibitors | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | NOVARTIS AG (CH) | 2023-12-07 | — | — | US | disclosed |
| EP-4237417-A1 | INTERLEUKIN-17 INHIBITORS | Novartis AG (CH) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022091056-A1 | INTERLEUKIN-17 INHIBITORS | NOVARTIS AG (CH) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | IL17A, IL2, IL18 | CIT 1830/4885RUVBL1 3261/4885ITGB1 726/4885 |
| US-12600728-B2 | Interleukin-17 inhibitors | IL17A, IL2, IL1B | CIT 1570/4885RUVBL1 4428/4885ITGB1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.